Introduction {#S1}
============

Hepatocellular carcinoma (HCC) is an international health problem with annual diagnosis of about 854,000 new cases \[[@ref1]\]. It has been projected that by 2030, this number will increase by 53% \[[@ref2]\]. There are multiple choices for the treatment of HCC including surgical resection, liver transplantation, trans-arterial chemoembolization and percutaneous local ablation \[[@ref3]\]. Microwave ablation (MWA) is one form of local thermal ablation which is a new promising technique for HCC treatment. It depends on production of electromagnetic waves which force dipole water molecules to continuously rotate billions of times per second with the oscillating electric field typically at 900 to 2500 MHz leading to production of heat \[[@ref4]\]. MWA displays several theoretical advantages over radiofrequency ablation (RFA) including the reduced "heat sink" effect \[[@ref5]\], less tissue charring during ablation, thus being efficient for achieving a larger ablation zone \[[@ref6]\], and deeper and faster penetration with a short ablation time \[[@ref7]\]. The new version of MWA machines is equipped with a modern shaft which is provided by a cooling system to prevent overheating and protect the skin from burns. This addition increases the amount of energy delivered to the target tissue to facilitate creation of large ablation zones \[[@ref8]\]. Eventually, larger lesions could be treated by two options, either by repositioning of the antennae \[[@ref9]\] or through the use of multiple antennae simultaneously \[[@ref10]\]. In fact, with the introduction of the new system, over 80% of complete ablation could be achieved in large HCC nodules (up to 8 cm in diameter) \[[@ref11]\].

The high recurrence rate after HCC treatment is the main cause of the dismal prognosis \[[@ref12]\]. The French Study Group for Liver Transplantation reported a new predictive model for detection of HCC recurrence: the AFP score, based on tumor size, number of nodules and AFP values \[[@ref13]\]. The AFP has a curial role in tumor differentiation and vascular invasion. Its predictive value for detection of HCC recurrence is increased by combining it with the size and the number of the tumors \[[@ref13], [@ref14]\]. The AFP score was found to be superior to Milan criteria in selection and predicting recurrence of HCC candidates for liver transplantation \[[@ref13], [@ref15]\].

Aurora B kinase is considered a member of the serine/threonine kinase family which is fundamental for accurate genomic stability \[[@ref16]\]. AURKB is crucial for correct chromosomal alignment and segregation \[[@ref17]\]. Aurora B kinase deletion will lead to chromosomal segregation failure, which is the cause of genomic instability and tumorigenesis \[[@ref18]\]. There are lots of human cancers which have shown high AURKB expression and it is significantly correlated with tumor aggressiveness \[[@ref19]\]. Recent studies reported that its up-regulation is significantly linked to the invasion of the portal vein and/or hepatic veins \[[@ref20], [@ref21]\]. It was noted that its aberrant expression in HCC has a predictive value in HCC recurrence after curative hepatectomy \[[@ref22]\]. To our knowledge, there is no study which reported the prognostic importance of AFP score and AURKB in HCC patients treated with microwave ablation. Thus, we aimed to investigate the clinical and prognostic significance of AFP score and AURKB in HCC patients managed by MWA.

Material and methods {#S2}
====================

A cross-sectional study, purposive sample where twenty-five patients with definite HCC on top of liver cirrhosis related to HCV who were referred to the Alexandria University Hepatobiliary Unit were included. A triphasic computed tomography (CT) abdomen and/or dynamic magnetic resonance imaging (MRI) were performed to confirm the diagnosis of HCC, determine the site, size and numbers of the tumors and to rule out invasion of the portal vein and hepatic veins. Inclusion criteria were early-stage HCC according to Barcelona Clinic Liver Cancer (BCLC 0/A-B), which includes either single nodule not greater than 5 cm, or up to three nodules with the largest of 3 cm in maximum diameter. Child C patients, patients with portal venous thrombosis or distant metastasis, or who received other treatment technique before MWA were excluded. All patients were subjected to clinical examination. Severity of liver disease was assessed by the modified Child-Pugh classification. Alfa-fetoprotein (AFP) was assessed by enzymelinked immunosorbent assay. A simplified AFP score version was used for calculation of the AFP score \[[@ref13]\] with classification of patients according to tumor size (\< 3 cm, 3-6 cm and \> 6 cm) and according to number of nodules (1-3 and ≥ 4) then patients were classified into high and low risk of recurrence based on a cutoff value of 2.

All nodules were chosen for ablation by MWA using a 14 gauge AMICA probe and an AMICA 2.45 GHz generator (Italy). Wattage and duration used for ablation were chosen based on the manufacturer's guides. Biopsies from the tumor and the surrounding tissues were obtained just prior to MWA.

Aurora B kinase expression was assessed by immunohistochemistry of the tumor and the surrounding cirrhotic tissue according to streptavidin peroxidase technique using ab2254 (1 : 250; Abcam, USA) anti-body. Aurora B kinase expression was observed in the form of brown nuclear staining in the cellular population in all cases stained with the antibody. A CH 20 BIMF 200, Olympus microscope (China) was used for quantification of Aurora B kinase under a magnification of 400×. For pathological evaluation of each biopsy, 81 × 12 points (number of intersections in the grid used) were performed. All positively and negatively stained cells falling on the grid's intersections were counted and the mean score per biopsy was calculated. The positively stained points were expressed as percentage out of the total number of counted points. HCC grade was assessed according to the World Health Organization grading system \[[@ref23]\].

Follow-up {#S2_1}
---------

A triphasic CT was performed 4 weeks (to give time for post-ablation edema, which may give a false impression of recurrence, to resolve) after the MWA to assess the local response. Patients with residual tumor activity were retreated with MWA. Another follow-up triphasic CT was performed after 4 weeks. All patients were followed by performing triphasic CT every 3 months after complete ablation for 1 year to detect any recurrence of HCC.

Ethical statement {#S2_2}
-----------------

The study was performed in alignment with the revised Declaration of Helsinki (2013), and with Good Clinical Practice guidelines. Our study was approved by the Ethical Committee of the Faculty of Medicine, Alexandria University (IRB No. 00007555). Informed consent from all subjects included in the study was obtained.

Statistical analysis {#S2_3}
--------------------

Analysis was done using SPSS 20.0. Qualitative data were expressed as number and percentage. Quantitative data were expressed as range and mean ± standard deviation. *P* value less than 5% level is considered significant. The chi-square test was used to compare between different categorical variables. Fisher's exact or Monte Carlo correction for χ^2^ was used when more than 20% of the cells had an expected count less than 5.Student's *t*-test was used to compare between two studied groups of normally distributed quantitative variables. The Mann-Whitney test was used to compare between two studied groups with non-normally distributed quantitative variables. The Pearson coefficient test was used for correlation between two normally distributed quantitative variables. Comparison between more than two studied groups with abnormally distributed quantitative variables was done using the Kruskal-Wallis test. Correlation between two abnormally distributed quantitative variables was done using the Spearman coefficient test.

Results {#S3}
=======

Demographic data {#S3_1}
----------------

There was a male predominance in our studied sample: 19/25 (76.0%) were male with a mean age of 56.13 ±6.77 years, range (43.0-70.0) years.

Clinico-pathological characteristics of studied cases {#S3_2}
-----------------------------------------------------

Descriptive analysis of the studied cases according to clinico-pathological characteristics is illustrated in [Table 1](#T1){ref-type="table"}.

###### 

Descriptive analysis of the studied cases according to clinico-pathological characteristics

  Parameter           *n*                \%                  
  ------------------- ------------------ ------------------- ------
  AFP level (ng/ml)                                          
                      ≤ 100              16                  64.0
                      \> 100 -- ≤ 1000   7                   28.0
                      \> 1000            2                   8.0
                      Min.-Max.          2.40-1132.0         
                      Mean ±SD           194.8 ±330.3        
                      Median (IQR)       41.80 (8.1-178.9)   
  Child class                                                
                      A                  12                  48.0
                      B                  13                  52.0
  Tumor number                                               
                      1-3                23                  92.0
                      ≥ 4                2                   8.0
                      Min.-Max.          1.0-4.0             
                      Mean ±SD           1.72 ±1.02          
                      Median (IQR)       1.0 (1.0-2.5)       
  Tumor size (cm)                                            
                      ≤ 3                4                   16.0
                      \< 3-6             18                  72.0
                      \> 6               3                   12.0
                      Min.-Max.          2.0-7.50            
                      Mean ± SD          4.44 ±1.40          
                      Median (IQR)       4.20 (3.5-5.2)      
  Pathologic grade                                           
                      II                 12                  48.0
                      III                13                  52.0
  AFP score                                                  
                      ≤ 2                13                  52.0
                      \> 2               12                  48.0
                      Min.-Max.          0.0-6.0             
                      Mean ±SD           2.16 ±1.57          
                      Median (IQR)       2.0 (1.0-3.0)       

Response to MWA therapy {#S3_3}
-----------------------

There was no significant difference between patients who achieved complete ablation and those who showed recurrence regarding Child-Pugh classes (χ^2^ = 1.924, *p* = 0.165), tumor size (χ^2^ = 4.081, ^MC^*p* = 0.105), the number of tumor nodules (χ^2^ = 0.032, ^FE^*p* = 1.000) and the pathological grade of the tumor (χ^2^ = 0.051, *p* = 0.821). Serum AFP level and AFP score showed a statistically significant difference between patients who achieved complete ablation and patients with recurrence (χ^2^ = 6.451, ^MC^*p* = 0.031) (χ^2^ = 9.0, *p* = 0.003), respectively. 78.6% of patients who achieved complete ablation after MWA were low-risk patients (AFP score ≤ 2). 81.8% of patients who showed recurrence were high-risk patients (AFP score \> 2) ([Table 2](#T2){ref-type="table"}).

###### 

Relation between response to MWA therapy and different parameters

                      Response to MWA therapy   Test of sig.   *p*                                          
  ------------------- ------------------------- -------------- ------------ -------------- ---------------- -------------------
  Child class                                                                              χ^2^ = 1.924     0.165
                      A                         7              63.6         5              35.7             
                      B                         4              36.4         9              64.3             
  Tumor size (cm)                                                                          χ^2^ = 4.081     ^MC^*p* = 0.105
                      ≤ 3                       1              9.1          3              21.4             
                      \> 3-6                    7              63.6         11             78.6             
                      \> 6                      3              27.3         0              0.0              
                      Min.-Max.                 2.0-7.50       2.60-5.50    *t* = 1.393    0.185            
                      Mean ±SD                  4.90 ±1.77     4.08 ±0.93                                   
                      Median                    4.50           4.05                                         
  AFP level (ng/ml)                                                                        χ^2^ = 6.451\*   ^MC^*p* = 0.031\*
                      ≤ 100                     4              36.4         12             85.7             
                      \> 100 -- ≤ 1000          5              45.5         2              14.3             
                      \> 1000                   2              18.2         0              0.0              
  Pathologic grade                                                                         χ^2^ = 0.051     0.821
                      II                        5              45.5         7              50.0             
                      III                       6              54.5         7              50.0             
  Tumor number                                                                             χ^2^ = 0.032     ^FE^*p* = 1.000
                      1-3                       10             90.9         13             92.9             
                      ≥ 4                       1              9.1          1              7.1              
  AFP score                                                                                χ^2^ = 9.0\*     0.003\*
                      ≤ 2                       2              18.2         11             78.6             
                      \> 2                      9              81.8         3              21.4             
                      Min.-Max.                 1.0-6.0        0.0-3.0      *U* = 16.0\*   \< 0.001\*       
                      Mean ±SD                  3.36 ±1.29     1.21 ±1.05                                   
                      Median                    3.0            1.0                                          

*χ*^2^ -- chi square test, MC -- Monte Carlo, FE -- Fisher exact test, t -- Student t-test, U -- Mann-Whitney test, \*statistically significant at p ≤ 0.05

Comparison between high-risk (AFP score \> 2) and low-risk (AFP score ≤ 2) patients regarding the pathological grade {#S3_4}
--------------------------------------------------------------------------------------------------------------------

The high-risk and low-risk groups showed a statistically significant difference regarding the pathological grade of the tumor (χ^2^ = 4.891, *p* = 0.027) ([Table 3](#T3){ref-type="table"}).

###### 

Comparison between high-risk (AFP \> 2) and low-risk (AFP ≤ 2) patients regarding the pathological grade

  -------------------------------------------------------------------------
  Pathologic\   AFP score   Test\     *p*                           
  grade                     of sig.                                 
  ------------- ----------- --------- ----- ------ ---------------- -------
  II            9           69.2      3     25.0   χ^2^ = 4.891\*   0.027

  III           4           30.8      9     75.0                    
  -------------------------------------------------------------------------

χ^2^ -- chi square test

Correlation between AFP score and pathological grade {#S3_5}
----------------------------------------------------

There was a significant positive correlation between AFP score and the pathological grade of the tumor (*r* = 0.467, *p* = 0.019) ([Table 4](#T4){ref-type="table"}).

###### 

Correlation between AFP score with the pathological grade (*n* = 25)

                     AFP score   
  ------------------ ----------- -------
  Pathologic grade   0.467       0.019

r~s~ -- Spearman coefficient

Aurora B kinase expression in hepatocellular carcinoma and non-tumor liver tissue {#S3_6}
---------------------------------------------------------------------------------

Aurora B kinase showed significantly high expression in HCC tumor tissue compared to corresponding non-tumor tissues (*p* \< 0.001), with an average expression score of 63.56 ±17.64 and 20.76 ±2.82 respectively ([Table 5](#T5){ref-type="table"}).

###### 

Aurora B kinase expression in HCC and non-tumoral liver tissue

                 Aurora B kinase expression   Z              *p*     
  -------------- ---------------------------- -------------- ------- ----------
  Min.-Max.      17.0-27.0                    39.0-89.0      4.375   \< 0.001
  Mean ±SD       20.76 ±2.82                  63.56 ±17.64           
  Median (IQR)   20.0                         69.0                   

Z -- Wilcoxon signed ranks test, p -- p-value for comparing between liver and tumor

Immunohistochemical staining of both tumoral and non-tumoral tissues showed that Aurora B kinase expression was higher in tumoral tissue than its non-tumoral counterparts ([Fig. 1A, B](#F1){ref-type="fig"}).

![Comparison of Aurora B kinase expression between HCC tissue and non-tumoral liver tissue smears. **A)** Aurora B kinase staining in grade II HCC. Note the nuclear staining pattern (Aurora B kinase antibody, streptavidin peroxidase technique, 200×). **B)** Aurora B kinase antibody staining in nontumoral cirrhotic liver smears. Note the positive nuclear staining observed in several tumor cells seen in this cluster of reactive hepatocytes (Aurora B kinase antibody, streptavidin peroxidase technique, 400×)](CEH-6-40584-g001){#F1}

Aurora B kinase expression in HCC and its relation with different clinico-pathological parameters {#S3_7}
-------------------------------------------------------------------------------------------------

There was no significant relation between Aurora B kinase expression and sex of the patients. There was no significant difference in expression of Aurora B kinase between different groups of Child class, size of the tumor and serum AFP levels. However, a significant difference was observed between the scores of Aurora B kinase expression in cases where the number of nodules was 3 or less and those with 4 or more tumors (U = 2.0, *p* = 0.035). The mean level of Aurora B kinase among the high-risk group was 71.58 ±16.49 while in the low-risk group it was 56.15 ±15.78. There was a statistically significant difference in the expression of Aurora B kinase between the two groups (U = 41.50, *p* = 0.047) ([Table 6](#T6){ref-type="table"}).

###### 

Aurora B kinase expression in HCC and its relation with different clinico-pathological parameters

  Parameters                *n*                 Aurora B kinase expression in HCC   Test of sig.   *p*                          
  ------------------------- ------------------- ----------------------------------- -------------- -------------- ------------- ----------
  Sex                                                                                                             U = 48.50     0.588
                            Male                19                                  42.0-89.0      64.32 ±17.94   69.0          
                            Female              6                                   39.0-79.0      61.17 ±18.05   62.50         
  Child class                                                                                                     U = 75.0      0.870
                            A                   12                                  39.0-89.0      62.75 ±17.29   61.50         
                            B                   13                                  43.0-88.0      64.31 ±18.63   73.0          
  Tumor number                                                                                                    U = 2.0\*     0.035
                            1-3                 23                                  39.0-89.0      61.48 ±16.81   54.0          
                            ≥ 4                 2                                   87.0-88.0      87.50 ±0.71    87.50         
  Tumor size (cm)                                                                                                 H = 5.297     0.071
                            ≤ 3                 4                                   43.0-54.0      47.50 ±4.80    46.50         
                            \< 3-6              18                                  39.0-88.0      64.17 ±17.69   71.0          
                            \> 6                3                                   76.0-89.0      81.33 ±6.81    79.0          
  AFP level (ng/ml)                                                                                               H = 0.003     0.999
                            ≤100                16                                  39.0-89.0      63.50 ±19.25   62.0          
                            \>100 -- ≤1000      7                                   42.0-79.0      64.0 ±15.41    69.0          
                            \>1000              2                                   47.0-78.0      62.50 ±21.92   62.50         
  AFP score                                                                                                       U = 41.50\*   0.047
                            ≤ 2                 13                                  39.0-82.0      56.15 ±15.78   50.0          
                            \> 2                12                                  42.0-89.0      71.58 ±16.49   77.50         
  Response to MWA therapy                                                                                         U = 74.0      0.869
                            Recurrence          11                                  39.0-89.0      64.45 ±18.61   69.0          
                            Complete ablation   14                                  43.0-88.0      62.86 ±17.51   62.0          
  Pathologic grade                                                                                                U = 0.00\*    \< 0.001
                            II                  12                                  39.0-54.0      46.33 ±4.29    46.0          
                            III                 13                                  69.0-89.0      79.46 ±5.88    78.0          

U -- Mann-Whitney test, H -- H for Kruskal-Wallis test, p -- p-value for comparing between the studied categories

There was a statistically significant difference of Aurora B kinase expression between pathological grade II and pathological grade III (U = 0.00, *p* \< 0.001) ([Fig. 2A, B](#F2){ref-type="fig"}).

![Comparison of Aurora B kinase expression between grade II HCC and grade III HCC. **A)** Aurora B kinase staining in grade II HCC. Note the nuclear staining pattern (Aurora B kinase antibody, streptavidin peroxidase technique, 200×). **B)** Aurora B kinase staining in grade III HCC showing intense nuclear positivity (Aurora B kinase antibody, streptavidin peroxidase technique, 400×)](CEH-6-40584-g002){#F2}

Regarding the prognostic significance of Aurora B kinase expression, there was no significant difference in Aurora B kinase expression between patients who achieved complete ablation and patients with recurrence (*p* = 0.869).

Correlation between Aurora B kinase expression in HCC and different clinico-pathological parameters {#S3_8}
---------------------------------------------------------------------------------------------------

Statistically significant positive correlations were observed between the expression of Aurora B kinase on one hand and the size of the tumor, the number of tumor nodules, AFP score and the pathological grade of the tumor on the other hand. No correlation was found between Aurora B kinase score and Child class ([Table 7](#T7){ref-type="table"}).

###### 

Correlation between Aurora B kinase expression in HCC and different clinico-pathological parameters

  Parameters         Aurora in HCC (tumor)   
  ------------------ ----------------------- ----------
  Tumor size         0.549\*                 0.004
  Tumor number       0.442\*                 0.027
  AFP score          0.471\*                 0.018
  Pathologic grade   0.867\*                 \< 0.001
  Child class        0.033                   0.874

r~s~ -- Spearman coefficient

Discussion {#S4}
==========

Microwave ablation is a new promising minimally invasive thermal modality for HCC treatment \[[@ref24]\]. In spite of increasing numbers of patients who prefer microwave ablation with satisfactory complete ablation, recurrence can occur, which represents an important problem \[[@ref25], [@ref26]\].

Our study showed that Child-Pugh classification has no significant impact on prognosis of HCC after MWA. A similar observation was made by Wang *et al*. \[[@ref24]\].

Our study showed the significant importance of serum AFP level in predicting HCC recurrence after MWA. Similar observations were also reported by Notarpaolo *et al*. \[[@ref15]\], who concluded that there was a significant role of AFP level in the probability of HCC recurrence after liver transplantation. In contrast, Liang *et al*. \[[@ref27]\], who studied the prognostic factors affecting the survival after MWA, reported that the pre-ablation serum AFP level was not related to prognosis.

It has been found in the present study that AFP score can effectively predict the response to MWA among HCC patients. Shaker *et al*. \[[@ref28]\] conducted a study to investigate the validity of the use of the AFP score as a predictor of response in HCC patients after loco-regional treatment \[radiofrequency ablation (RFA), transarterial chemoembolization (TACE)\] and found that both RFA and TACE groups of patients with an AFP score less than or equal to 2 had a higher complete response rate and lower recurrence rate than patients with an AFP score more than 2. Similar observations were reported by Notarpaolo *et al*. \[[@ref15]\], who found that the utility of the AFP score was better than the Milan criteria in selection of patients who were at low risk of recurrence, even if beyond Milan criteria. Thus, they stated that patients who were within Milan criteria, but had high AFP scores, should be paid special attention before considering them eligible for liver transplantation. Careful downstaging to AFP score ≤ 2 in these patients by percutaneous ablation technique can be advised before transplantation with a fairly low risk of recurrence and excellent rate of survival. These expansions in the selection criteria to the AFP score for patients who were beyond the Milan criteria might result in a considerable increase of about 14% in the number of patients eligible for liver transplantation.

The present study showed a strong association between the AFP score and the pathological grade of the tumor. Similar results were obtained by Notarpaolo *et al*. \[[@ref15]\].

In the present study, AURKB was over-expressed in tumoral more than non-tumoral specimens. Similar observations were reported by Tovuu *et al*. \[[@ref29]\], who studied the expression of the Aurora B kinase gene in both HCC tumor and non-tumor liver tissues and explained its role in HCC. They found that the expression of Aurora B kinase in tumor tissues was significantly higher than in non-tumor tissues. These results go hand in hand with the findings of Yasen *et al*. \[[@ref20]\] as it has a significant role in hepatocarcinogenesis.

In our study, Aurora B kinase expression was correlated with the size of the tumor, the number of tumor nodules and the pathological grade of the tumor. These results are consistent with those of Lin *et al*. \[[@ref30]\], who reported that Aurora B kinase mRNA expression in HCC was correlated with the tumor size and the tumor grade. Similar results were obtained by Sistayanarain *et al*. \[[@ref21]\], who concluded that Aurora-B kinase was over expressed in moderately to poorly differentiated HCC.

In our study we also found no significant difference of Aurora B kinase expression between different groups of AFP levels. In contrast, Lin *et al*. \[[@ref30]\] reported that Aurora B overexpression was associated with high serum AFP level. In our study the lack of the correlation could be explained by the low serum level of AFP in most of our patients (AFP level \< 100 in 64% of patients and \> 1000 in only 8%).

Our study demonstrated that Aurora B kinase expression was not associated with the reserve of liver function (Child-Pugh). Similar results were obtained by Lin *et al*. \[[@ref30]\]. Contradictory results were reported by Tovuu *et al*. \[[@ref29]\], who found that high Aurora B kinase gene expression showed a significant correlation with the severity of chronic liver disease.

Our study showed no relation between Aurora B kinase and HCC recurrence. Lin *et al*. \[[@ref30]\] stated that Aurora B kinase overexpression was associated with early recurrence and poor prognosis of surgically resected HCC. Also, contradictory results were reported by Yasen *et al*. \[[@ref20]\], who declared that Aurora B kinase was significantly overexpressed in HCC patients with vascular invasion (portal vein and/or hepatic veins), advanced stages and capsular invasion; hence, it was considered to be a marker for poor prognosis and recurrence.

Since up-regulation of Aurora B kinase is significantly linked to the invasion of the portal vein and/or hepatic veins and high HCC stage and in turn to HCC recurrence \[[@ref20], [@ref21]\], the difference between our results and the results of other studies regarding the lack of correlation between Aurora B kinase expression in HCC and both Child class and recurrence of the tumor might be explained by the selection criteria in our study, which was limited to Child A and B, with exclusion of patients with Child C, patients with vascular invasion and patients with extra-hepatic metastases.

Conclusions {#S5}
===========

In conclusion, it is evident that the AFP score not only serves as a score that could distinguish correctly and accurately between patients who are at low and high risk of HCC recurrence after microwave ablation but also can bring up more information about the tumor behavior, making the identification of aggressive tumors possible, even with reasonable tumor size and number. Aurora B kinase could be used as a biomarker for aggressiveness of HCC tumor (larger size, multinodularity and high grade) but not for prediction of HCC recurrence after microwave ablation.

We recommend conducting further studies with a larger sample size and longer followup period to study the predictive value of Aurora B kinase and AFP score for HCC recurrence after microwave ablation.

The main limitation of our study is the small sample size. The main strength is that it is a prospective study. Another strength is the novelty of the idea, since the role of AFP score and Aurora B kinase in HCC recurrence after microwave ablation has not been studied before.
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